Skip to main content

Drug Interactions between DurAct and plasminogen, human

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

bromfenac plasminogen, human

Applies to: DurAct (bromfenac) and plasminogen, human

MONITOR CLOSELY: Coadministration of plasminogen with anticoagulants, antiplatelets, or other agents that interfere with normal coagulation may prolong or worsen bleeding from active lesions and wounds. Plasminogen deficiency type 1 is characterized by the formation of fibrin-rich lesions on mucous membranes. Replacement therapy temporarily corrects plasminogen deficiency and reduces or resolves extravascular fibrinous lesions, which may prolong or worsen bleeding from any active lesion (disease-related or not), including GI bleeding, hemoptysis, epistaxis, vaginal bleeding, or hematuria. Clinical data are currently lacking.

MANAGEMENT: Caution is advised if plasminogen is used in patients taking anticoagulants, antiplatelets, or other agents that interfere with normal coagulation. Clinical and laboratory monitoring are recommended for 4 hours after infusion. If a patient develops any GI bleeding or bleeding from any other site that persists longer than 30 minutes, seek emergency care and discontinue plasminogen immediately.

References (1)
  1. (2022) "Product Information. Ryplazim (plasminogen, human)." Prometic Biotherapeutics Inc

Drug and food interactions

Moderate

bromfenac food

Applies to: DurAct (bromfenac)

ADJUST DOSE: In-vivo studies have demonstrated that the absorption of bromfenac is greatly reduced if the drug is taken within three and one-half hours following a high fat meal. The concomitant administration of a high fat meal has led to a 75% reduction in peak plasma concentrations and a 60% reduction in total area under the curve. The mechanism has not been described.

MANAGEMENT: An increased dosage of bromfenac (from 25 to 50 mg) may be needed if a high fat meal is consumed. The clinician may want to warn the patient about subtherapeutic analgesic effects if high fat meals are regularly consumed.

References (1)
  1. "Product Information. DurAct (bromfenac)." Wyeth-Ayerst Laboratories

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer